ANALYSING THE VOLUME OF DRUG CONSUMPTION IN INPATIENT TREATMENT OF EPILEPSY

The article presents the results of the study of the volume of consumption of medicinal drugs for the treatment of patients diagnosed with epilepsy. As a result of retrospective processing of case histories (continuous sampling for 2021-2023) obtained in the inpatient department of the Clinic of Nervous Diseases named after A.Y. Kozhevnikov of Sechenov University, we identified medicines with the highest NDDD value (number of defined daily doses) for each of the 8 allocated clinical and statistical groups. Among all clinical and statistical groups, the G40.0 group had the highest consumption. In clinical and statistical groups G40.0, G40.8 and G40.9, valproic acid and levetiracetam were found to have the highest NDDD value. In addition, the consumption volume analysis showed that in clinical and statistical group G40.8, the neuroleptics quetiapine and teraligene are used relatively more frequently than in other diagnoses. In clinical and statistical groups G40.1, G40.2, and G40.4, the medicines valproic acid, levetiracetam, and lamotrigine were used, respectively. B vitamins accounted for the highest consumption among all clinical and statistical groups, except for G40.2. The results obtained may become the basis for the development of recommendations to optimize the use of medicines and improve the quality of drug care for patients with epilepsy at the inpatient stage.